Marker Therapeutics, Inc.

Monthly Archives: November 2016


TapImmune President John Bonfiglio to Present a Corporate Update at Biotech and Money Investival Showcase

TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment…

Read More

TapImmune Commences Trading on the Nasdaq Capital Market

…Jacksonville, Fla. – November 8, 2016 – TapImmune, Inc., (NASDAQ: TPIV), an immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, today announced that its common stock has commenced trading on The Nasdaq Capital Market from the opening of market today.

Read More

TapImmune Approved for Listing on the Nasdaq Capital Market

…JACKSONVILLE, Fla., Nov. 3, 2016 /PRNewswire/ — TapImmune, Inc., (TPIV), an immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, today announced that its common stock has been approved to begin trading on The Nasdaq Capital Market. The company’s common stock will begin trading under the symbol “TPIV” at the opening of trading on Tuesday, November 8, 2016.

Read More

TapImmune Announces Commercialization Pathway For Its HER2neu Vaccine

…Jacksonville FL, November 1, 2016 – TapImmune, Inc. (OTCMKTS: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, is providing an update on the progression of a HER2neu vaccine into clinical trials. The vaccine (TPIV 110) consists of 4 proprietary Class II antigens and 1 proprietary Class I antigen.

Read More